By Pat Anson. Many patients have learned – the hard way – that nerve medications known as gabapentinoids have over a dozen potential side effects,...
3 days ago

Neural Ice: Is this long-lasting pain therapy revolutionizing treatment?
2 weeks ago

Virpax Pharmaceuticals advances development of NES100, a breakthrough nasal spray using nanotechnology to deliver pain relief without opioid-related side...
2 weeks ago

Ijeoma Uchegbu discusses nanomedicine's role in improving medication adherence and developing non-addictive pain relief solutions at ELRIG Drug Discovery...
2 weeks ago

Researchers have developed a non-addictive painkiller that remains inactive until it reaches sites of chronic pain. Instead of dulling the nerves that send...
3 weeks ago

Axonis Therapeutics, a biotech company that has been quietly operating for the last five years, has raised $115 million after retooling its drug pipeline.
1 month ago

Vertex Pharmaceuticals is on the verge of gaining an FDA approval for suzetrigine (VX-548), a nonaddictive oral treatment that is on track to become the first...
1 month ago

The global non-opioid pain patch market size was valued at around USD 828.3 million in 2023 and is estimated to grow at 6.6% CAGR from 2024 to 2032 driven...
1 month ago

A deep-learning model found metabolites and drugs that could be repurposed for non-addictive and non-opioid options to treat chronic pain.
1 month ago

AI is being harnessed by a partnership between IBM and US healthcare group Cleveland Clinic to help identify non-opioid chronic pain treatments.
1 month ago